IDIAP Jordi Gol (IDIAPJGol)

This sponsor has funded 8 studies across 3 countries.

PAS funded by this sponsor.
EU PAS ID Status RMP requirement Title Protocol uploaded Results uploaded
18510 Planned Not included in RMP Assessment of cardiovascular effects of non-insulin glucose-lowering agents. Major cardiovascular events in new users of non-insulin glucose-lowering... Yes No
19017 Finalised Not included in RMP Impact of medication adherence on mortality and cardiovascular morbidity: a population-based retrospective cohort study. IMPACT study Yes No
36180 Planned Not included in RMP Opioid drug utilization and comparative safety: a population-based cohort study No No
36689 Finalised Not included in RMP Comparative safety study of tramadol and codeine users: a population-based cohort study Yes Yes
37205 Finalised Not included in RMP Sociodemographic, clinical and pharmacological characteristics associated with the prognosis of patients with SARS-CoV-2 infection (Características... Yes No
37675 Finalised Not included in RMP Assessing exposure to cardiovascular therapy, anxiety depressive syndrome treatment and anti-infectives during pregnancy and breastfeeding (Drug... Yes No
48017 Planned Not included in RMP Risks of pharmacological interactions of direct oral anticoagulants: thrombotic and hemorrhagic events leading to hospital admission in Catalonia.... No No
104349 Planned Not included in RMP Utilization of antidementia treatments: a large multinational-network population-based study. No No

PAS by Risk Management Plan (RMP) requirement

IDIAP Jordi Gol (IDIAPJGol)

The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.

Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.